Dupixent® Litigation Attorneys

Dupixent® (dupilumab) is a prescription medicine that works by calming overactive parts of the immune system. It was first approved by the U.S. Food and Drug Administration (FDA) in 2017. Doctors prescribe Dupixent® to treat several chronic conditions linked to inflammation, including moderate-to-severe eczema (atopic dermatitis), asthma, chronic sinus problems with nasal polyps, and eosinophilic esophagitis.

Recently, there have been medical reports suggesting an association between Dupixent® and Cutaneous T-Cell Lymphoma (CTCL), which is a rare type of skin cancer. In fact, several recent studies published in medical journals have shown a significantly increased incidence of this type of cancer among users of Dupixent®.

Cutaneous T-Cell Lymphoma (CTCL)

Cutaneous T-Cell Lymphoma (CTCL) is a rare type of cancer that begins in the body’s T-cells (a kind of white blood cell that normally helps fight infection) and mainly affects the skin. Instead of working normally, these cancerous T-cells collect in the skin, which can cause patches, rashes, itching, or tumors that may look similar to eczema or psoriasis. CTCL tends to develop slowly, though some forms can be more aggressive.

The main subtypes of CTCL include:

• Mycosis Fungoides – the most common form, often appearing first as flat, scaly patches or plaques on the skin.
• Sézary Syndrome – a more aggressive form where cancerous T-cells are found in the blood as well as the skin, often with widespread redness and itching.
• Primary Cutaneous CD30+ Lymphoproliferative Disorders – usually includes lymphomatoid papulosis (which causes recurring bumps that may heal on their own) and primary cutaneous anaplastic large cell lymphoma (which may cause larger skin tumors).

Other rare types, such as subcutaneous panniculitis-like T-cell lymphoma and extranodal NK/T-cell lymphoma, which are much less common.

Contact Our Defective Medical Products Lawyers

If you or a loved one used Dupixent® and were diagnosed with Cutaneous T-Cell Lymphoma (CTCL) or any of the subtypes listed above, you might be eligible to pursue compensation through a Dupixent® lawsuit.

Please contact Parafinczuk Wolf at 954-462-6700 for a free consultation.